The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 7, 2001, Pages 1119-1127

  Worz, C R ^a   Bottorff, M ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Coronary artery disease; Cytochrome P450; Drug metabolism; Drug drug interactions; HMG CoA reductase inhibitors; Hyperlipidemia; Myalgia; Myopathy; Rhabdomyolysis; Statins

Indexed keywords

ALFENTANIL; ALPRAZOLAM; ASTEMIZOLE; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CISAPRIDE; CLINDAMYCIN; CLONAZEPAM; COCAINE; CYCLOSPORIN; CYTOCHROME P450; DILTIAZEM; ERYTHROMYCIN; ETOPOSIDE; FELODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIPRAMINE; ITRACONAZOLE; LIDOCAINE; LORATADINE; LOSARTAN; MEVINOLIN; MIBEFRADIL; NEFAZODONE; PLACEBO; PRAVASTATIN; RIFAMPICIN; SIMVASTATIN; UNINDEXED DRUG;

AREA UNDER THE CURVE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ENZYME INDUCTION; ENZYME INHIBITION; FOOD DRUG INTERACTION; HUMAN; MYOPATHY; MYOSITIS; PATIENT MONITORING; REVIEW; RHABDOMYOLYSIS;

AGED; ANTILIPEMIC AGENTS; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; DILTIAZEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GUIDELINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISOENZYMES; ITRACONAZOLE; LOVASTATIN; MALE; MIDDLE AGED; MUSCULAR DISEASES; PRAVASTATIN; RHABDOMYOLYSIS; SIMVASTATIN;

EID: 0034937089     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.7.1119     Document Type: Review

References (47)

1. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
2. Mevacor® prescribing information
3. Zocor® prescribing information
4. Pravachol® prescribing information
5. Lescol® prescribing information
6. Lipitor® prescribing information
7. Baycol™ prescribing information Physicians'
8. Major cytochrome P450 families: Implications in health and liver diseases
9. Update: Clinically significant cytochrome P450 drug interactions
10. Cytochrome P450: New nomenclature and clinical implications
11. Understanding drug-drug interactions
12. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
13. For the Adverse Drug Events Prevention Study Group: The costs of adverse drug events in hospitalized patients
14. Clinical pharmacokinetics of 3-hydroxy-3-methylglytaryl-coenzyme A reductase inhibitors
15. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 enzymes involved
16. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-) - Fluvastatin
17. Potential interaction between warfarin and
18. Biotransformation of pravastatin sodium in humans
19. Clinical Pharmacokinetics of Pravastatin
20. Interaction of diltiazem with lovastatin and
21. Effect of itraconazole on the pharmacokinetics of atorvastatin
22. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
23. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
24. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations
25. Rhabdomyolysis associated with lovastatin and erythromycin use
26. Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor
27. Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells
28. Rhabdomyolysis from the coadministration of lovastatin and the antifungalagent itraconazole
29. Lovastatin and rhabdomyolysis
30. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations
31. Rhabdomyolysis and renal injury with lovastatin use
32. Diltiazem myopathy
33. [Rhabdomyolysis in patients treated with simvastatin/cyclosporin: Role of the hepatic cytochrome P450 enzyme.]
34. Myositis and rhabdomyolysis associated with current use of simvastatin and nefazodone
35. Drug-interaction-induced rhabdomyolysis
36. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: Erythromycin and ethinyl estradiol
37. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin
38. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals
39. Rhabdomyolysis due to interaction of simvastatin with mibefradil
40. [Rhabdomyolysis with pravastatin and Type I macrocreatine kinase.]
41. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients
42. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
43. Efficacy and safety of pravastatin vs. simvastatin after cardiac transplantation
44. [Rhabdomyolysis during pravastatin treatment.]
45. Myoglobinuric renal failure due to long-standing lovastatin therapy in a patient with pre-existing chronic renal insufficiency